Gastrointestinal Stromal Tumors

Česká verzia

Authors: J. Žabka
Authors place of work: Chirurgické oddělení, Klatovská nemocnice, a. s., Klatovy
Published in the journal: Klin Onkol 2011; 24(3): 187-194
Category: Reviews

Summary

Gastrointestinal stromal tumours (GISTs) are the most common group of mesenchymal tumours affecting the gastrointestinal tract. Despite this, GISTs are relatively rare, since all mesenchymal tumours constitute just 1 percent of all primary GI cancers. Most often, GISTs affect the stomach and proximal small intestine but can be found in any section of the alimentary tract, including, occasionally, the omentum, mesentery and peritoneum. Virtually all GISTs (especially those larger than 1 cm) have malignant potential. Malignant potential of a tumour increases with its size and its mitotic rate, and it also depends on its anatomic location: intestinal GISTs are more aggressive than gastric tumours. Treatment of GISTs was revolutionized when it was discovered that mutational activation of KIT or PDGFRA stimulates the growth of these cancer cells. Mutational activation of KIT or PDGFRA led to abnormal activation of receptor tyrosine kinase and uncontrolled oncogenic signalling. This uncontrolled oncogenic signalling can be specifically targeted therapeutically with small molecule inhibitors of the receptor tyrosine kinase (imatinib, sunitinib). All GISTs ≥ 2 cm in size should be resected. To reduce disease recurrence, adjuvant imatinib therapy is recommended for all high-risk patients after resection. Neoadjuvant therapy is recommended for primarily unresectable tumours or a limited amount of potentially resectable metastatic disease. The goal of treatment is to reduce tumour size, thus facilitating complete surgical resection and increasing the likelihood of organ preservation.

Key words:
GIST – KIT – diagnosis – surgical procedures – imatinib

The author declares he has no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Zdroje

1. Miettinen M, Lasota J. Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438(1): 1–12.

2. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005; 29(1): 52–68.

3. Demetri G, Morgan J, Raut C. Epidemiology, classification, clinical presentation, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST. UpToDate [on line]. Vystaveno17.11.2009. Available from: <http://www.uptodate.com/online/content/topic.do?topicKey=stb_tumr/8100&selectedTitle=1~51&source=search_result>.

4. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998; 11(8): 728–734.

5. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 2000; 13(10): 1134–1156.

6. Janeway KA, Liegl B, Harlow A et al. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res 2007; 67(19): 9084–9088.

7. Daum O, Vaněček T, Šíma R et al. Gastrointestinální stromální tumor: Současný pohled. Klin Onkol 2006; 19(4): 201–211.

8. Daum O, Linke Z, Vaněček T et al. Gastrointestinální strumální tumor. [online]. Vystaveno 16.4.2008. Dostupné z: <http://www.gist.nadory.cz/>.

9. Ernst SI, Hubbs AE, Przygodzki RM et al. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 1998; 78(12): 1633–1636.

10. Lasota J, Jasinski M, Sarlomo-Rikala M et al. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999; 154(1): 53–60.

11. Nilsson B, Bümming P, Meis-Kindblom JM et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 2005; 103(4): 821–829.

12. Tryggvason G, Gíslason HG, Magnússon MK et al. Gastrointestinal stromal tumors in Iceland, 1990–2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 2005; 117(2): 289–293.

13. Goettsch WG, Bos SD, Breekveldt-Postma N et al. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer 2005; 41(18): 2868–2872.

14. Kawanowa K, Sakuma Y, Sakurai S et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 2006; 37(12): 1527–1535.

15. Maeyama H, Hidaka E, Ota H et al. Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 2001; 120(1): 210–215.

16. Graadt van Roggen JF, van Velthuysen ML, Hogendoorn PC. The histopathological differential diagnosis of gastrointestinal stromal tumours. J Clin Pathol 2001; 54(2): 96–102.

17. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23(3): 70–83.

18. Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33(5): 459–465.

19. Huang HY, Li CF, Huang WW et al. A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: a subdivision of the original high-risk group on the basis of outcome. Surgery 2007; 141(6): 748–756.

20. Pink D, Schoeler D, Lindner T et al. Severe hypoglycemia caused by paraneoplastic production of IGF-II in patients with advanced gastrointestinal stromal tumors: a report of two cases. J Clin Oncol 2005; 23(27): 6809–6811.

21. Kocáková I, Špelda S, Vetchá H et al. Imatinib mesylate – the first effective molecularly targeted drug therapy for GIST. 6th Int. Congress: Perspective in colorectal cancer. Barcelona 2004, Proceeding book: 302.

22. Demetri G, Morgan J, Raut C. Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract. UpToDate [online]. Vystaveno 11.1.2010. Available from: <http://www.uptodate.com/online/content/topic.do?topicKey=stb_tumr/13782&selectedTitle=2~51&source=search_result>.

23. Huguet KL, Rush RM Jr, Tessier DJ et al. Laparoscopic gastric gastrointestinal stromal tumor resection: the mayo clinic experience. Arch Surg 2008; 143(6): 587–590.

24. Miettinen M, Sarlomo-Rikala M, Sobin LH et al. Esophageal stromal tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas. Am J Surg Pathol 2000; 24(2): 211–222.

25. Igwilo OC, Byrne MP, Nguyen KD et al. Malignant gastric stromal tumor: unusual metastatic patterns. South Med J 2003; 96(5): 512–515.

26. Huang CC, Yang CY, Lai IR et al. Gastrointestinal stromal tumor of the small intestine: a clinicopathologic study of 70 cases in the postimatinib era. World J Surg 2009; 33(4): 828–834.

27. Miettinen M, Furlong M, Sarlomo-Rikala M et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol 2001; 25(9): 1121–1133.

28. Demetri G, Morgan J, Raut C. Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors. UpToDate [on line]. Vystaveno 9.6.2009. Available from: <http://www.uptodate.com/online/content/topic.do?topicKey=stb_tumr/15134&selectedTitle=4~51&source=search_result>.

29. Kocáková I, Verchovski D, Špelda S et al. Therapy of GIST by Imatinib Mesylate (Glivec) – a Specific Inhibitor of the c-Kit Receptor Tyrosine Kinase. 16th Int. Congress on Anti-cancer Treatment. Paris 2005, Proceeding book: 251.

30. Kocáková I, Špelda S, Kocák I. Imatinib mesylate and sunitinib malate in the treatment of metastatic gastrointestinal stromal tumor, 19th Int. Congress on Anti-cancer Treatment. Paris 2008, Proceeding book: 218–219.

31. Kocáková I, Kocák I, Špelda S et al. Staging and prediction of response to imatinib mesylate (IM) therapy of metastatic or locally andvanced gastrointestinal stromal tumors (GIST) according to F-FDG PET and CT scan, one centre study. 19th Int. Congress on Anti-cancer Treatment. Paris 2008, Proceeding book: 219–220.

32. DeMatteo RP, Lewis JJ, Leung D et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231(1): 51–58.